Skip to main content
. 2020 Nov 5;21(21):8313. doi: 10.3390/ijms21218313

Figure 1.

Figure 1

Jumonji domain-containing protein 2B (JMJD2B) expression level was upregulated in liver X receptor α (LXRα) agonist-treated HepG2 cells and the liver of LXRα agonist-treated mice. (A–F) HepG2 cells were incubated with T0901317 for 24 h. (A) Intracellular TG were measured using a triglyceride (TG) assay kit. (B–E) mRNA levels of JMJD2B, NR1H3, SREBF1, fatty acid synthase (FAS), acetyl CoA carboxylase (ACC), and stearoyl-CoA desaturase 1 (SCD1) were measured by qPCR. Data are presented as means ± SD from three independent experiments. ** p < 0.01, *** p < 0.001 vs. untreated control. (F) Protein expression levels of JMJD2B, LXRα, SREBP1c, and FAS were measured by western blotting. The SREBP1c shown here is precursor form (125 KD). (G–I) C57BL/6J mice were administrated with T0901317 by oral gavage daily for 5 days. (G) Representative liver photographs. (scale bar = 1 cm) (H) Liver weight. (I) Protein levels of JMJD2B, LXRα, SREBP1c, and FAS were measured by western blotting. The SREBP1c shown here is mature form (68 KD). Densitometric analysis of band intensity is shown in Figure S1A. Data are presented as means ± SD from 6 mice (n = 6). * p < 0.05 vs. untreated control mice.